Nightingale is a high CBD strain that is 70% sativa. It was bred by crossing Harlitsu with a cannabis strain from America's west coast region. Noteworthy is the very low THC level of between 1% - 3% while CBD levels are much higher coming in at between 11% - 18%. This medicine has implications for the treatment of people of all ages from infants to geriatric patients as the low THC will not have a powerful effect on the psyche.
Nightingale produces above average yields in a flowering time of between 60 - 65 days with the harvest being 400 - 500 gr/m2. Outdoors its late September harvest date means that it will grow to maturity in fairly high latitudes if the weather is reliable, something that's not always a banker. In this environment 700 gr/plant or more can be produced to provide good medicine. Its buds are colourful with red and purple predominant. It should be noted that this strain can stretch a fair bit with the onset of flowering and so a short vegetative period and/or the use of either SOG or SCROG systems will result in improved yields as well as greater control and management of the plants overall size.
This medical strain has a very powerful fruity flavour that is reminiscent of blueberry, grape and jasmine. Therapeutic benefits and uses of Nightingale include alleviating the symptoms of Crohn's Disease, epilepsy, arthritis, cancer and other auto-immune problems.
Forget your maladies and sing like a bird with Nightingale high CBD medical strain.
|Type de Produit||Seeds THC|
|Génétique||Harlitsu x Unknown West Coast US|
|Variété||La plupart sativa|
|Type de floraison||Photopériode|
|Teneur en THC||1% - 3%|
|Teneur en CBD||11% - 18%|
|Rendement||Indoors: 400 - 500 gr/m2; Outdoors: 700 gr/plant +|
|Emplacement||En plein air, Intérieur|
|Période de floraison||60 - 65 days|
|Maladies||Arthrite, Cancer, Épilepsie, Maladie de Crohn|
|Saveur / Goût||Fruité, Jasmin, Myrtille, Raisin|
About Lineage Genetics